中国银屑病生物制剂及小分子药物治疗指南（2024版）

doi:10.35541/cjd.20240294

Abstract

Abstract: 【Abstract】 The treatment of psoriasis has entered an era of targeted therapy, and the application of biologics and small-molecule drugs has markedly improved the quality of life of patients, especially in the treatment of moderate to severe, refractory, and special types of psoriasis. In China, biologics that have been approved for marketing and used in the treatment of psoriasis include 9 agents belonging to 5 major categories, namely tumor necrosis factor-α inhibitors, interleukin-12/23 inhibitors, interleukin-23 inhibitors, interleukin-17A inhibitors, and interleukin-36 inhibitors; small-molecule drugs include 4 drugs belonging to 2 categories that inhibit different steps in the inflammatory cytokine pathways, namely phosphodiesterase 4 and Janus kinases （including tyrosine kinase 2）. How to use biologics and small-molecule drugs in a rational, effective and safe way has become an issue of great concern in clinical practice. To this end, experts in the field of diagnosis and treatment of psoriasis and related fields in China developed this guideline based on Chinese and international research data, clinical experience, as well as characteristics of Chinese patients with psoriasis after in-depth discussions. This guideline provides specific guidance for clinicians in terms of application principles and methods of major biologics and small-molecule drugs, efficacy and safety profiles, patient screening and monitoring, common problems and solutions, as well as considerations for their application in special populations.

Key words: Psoriasis, Biological products, Therapeutics, Biologic agents, Small-molecule drugs, Guidelines

Chinese Society of Dermatology, China Dermatologist Association, Dermatology & Venereology Specialized Committee of Chinese Association of Integrative Medicine. Guidelines for the treatment of psoriasis with biologics and small-molecule drugs in China （2024）[J]. Chinese Journal of Dermatology, 2024, 57(11): 976-997.doi:10.35541/cjd.20240294

References ［139］

［1］	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂治疗指南（2021）［J］. 中华皮肤科杂志, 2021,54（12）:1033⁃1047. doi: 10.35541/cjd.20210643.
［2］	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）［J］. 中华皮肤科杂志, 2023,56（7）:573⁃625. doi:10.35541/cjd.20220839.
［3］	Liu LF, Chen JS, Gu J, et al. Etanercept biosimilar （recombinant human tumor necrosis factor⁃α receptor Ⅱ: IgG Fc fusion protein） and methotrexate combination therapy in Chinese patients with moderate⁃to⁃severe plaque psoriasis: a multicentre, randomized, double⁃blind, placebo⁃controlled trial［J］. Arch Dermatol Res, 2020,312（6）:437⁃445. doi: 10.1007/s00403⁃019⁃02024⁃6.
［4］	Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis［J］. N Engl J Med, 2003,349（21）:2014⁃2022. doi: 10.1056/NEJMoa030409.
［5］	Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial［J］. Lancet, 2000,356（9227）:385⁃390. doi: 10.1016/S0140⁃6736（00）02530⁃7.
［6］	Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept［J］. J Rheumatol, 2006,33（4）:712⁃721.
［7］	De Simone C, Amerio P, Amoruso G, et al. Immunogenicity of anti⁃TNFα therapy in psoriasis: a clinical issue?［J］. Expert Opin Biol Ther, 2013,13（12）:1673⁃1682. doi: 10.1517/14712 598.2013.848194.
［8］	Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, et al. Immunogenicity of anti⁃TNF⁃alpha agents in autoimmune diseases［J］. Clin Rev Allergy Immunol, 2010,38（2⁃3）:82⁃89. doi: 10.1007/s12016⁃009⁃8140⁃3.
［9］	Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review［J］. Br J Dermatol, 2014,170（2）:261⁃273. doi: 10.1111/bjd.12654.
［10］	Yang HZ, Wang K, Jin HZ, et al. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double⁃blind, placebo⁃controlled multicenter trial［J］. Chin Med J （Engl）, 2012,125（11）:1845⁃1851. doi: 10. 3760/cma.j.issn.0366⁃6999.2012.11.001.
［11］	Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque⁃type psoriasis: a randomized, double⁃blind, placebo⁃controlled trial［J］. J Am Acad Dermatol, 2004,51（4）:534⁃542. doi: 10.1016/j.jaad.2004.02.021.
［12］	Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate⁃to⁃severe psoriasis: a phase Ⅲ, multicentre, double⁃blind trial［J］. Lancet, 2005,366（9494）:1367⁃1374. doi: 10.1016/S0140⁃6736（05）67566⁃6.
［13］	Syversen SW, Jørgensen KK, Goll GL, et al. Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune⁃mediated inflammatory diseases: a randomized clinical trial［J］. JAMA, 2021,326（23）:2375⁃2384. doi: 10.1001/jama.2021. 21316.
［14］	Menter A, Strober BE, Kaplan DH, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with biologics［J］. J Am Acad Dermatol, 2019,80（4）:1029⁃1072. doi: 10.1016/j.jaad.2018.11.057.
［15］	Saeki H, Mabuchi T, Asahina A, et al. English version of Japanese guidance for use of biologics for psoriasis （the 2022 version）［J］. J Dermatol, 2023,50（2）:e41⁃e68. doi: 10.1111/1346⁃8138.16691.
［16］	Cai L, Gu J, Zheng J, et al. Efficacy and safety of adalimumab in Chinese patients with moderate⁃to⁃severe plaque psoriasis: results from a phase 3, randomized, placebo⁃controlled, double⁃blind study［J］. J Eur Acad Dermatol Venereol, 2017,31（1）:89⁃95. doi: 10.1111/jdv.13746.
［17］	Lanna C, Zangrilli A, Bavetta M, et al. Efficacy and safety of adalimumab in difficult⁃to⁃treat psoriasis［J］. Dermatol Ther, 2020,33（3）:e13374. doi: 10.1111/dth.13374.
［18］	Alabas OA, Mason KJ, Yiu Z, et al. Effectiveness and survival of methotrexate versus adalimumab in patients with moderate⁃to⁃severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register （BADBIR）［J］. Br J Dermatol, 2023,189（3）:271⁃278. doi: 10. 1093/bjd/ljad179.
［19］	Jo SJ, Huang YH, Tsai TF, et al. Efficacy of guselkumab in difficult⁃to⁃treat psoriasis regions: data from VOYAGE 1 and VOYAGE 2 Asian subpopulations［J］. J Dermatol, 2023,50（9）:1180⁃1189. doi: 10.1111/1346⁃8138.16865.
［20］	Papp K, Thaçi D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double⁃blind, phase 3 trial［J］. Lancet, 2017,390（10089）:40⁃49. doi: 10.1016/S0140⁃6736（17）31189⁃3.
［21］	Gordon K, Papp K, Poulin Y, et al. Long⁃term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open⁃label extension study for patients from REVEAL［J］. J Am Acad Dermatol, 2012,66（2）:241⁃251. doi: 10.1016/j.jaad.2010.12. 005.
［22］	刘鸿伟, 胡雪英, 雷东春, 等. 阿达木单抗治疗重度斑块状银屑病的临床观察［J］. 中华皮肤科杂志, 2020,53（9）:744⁃746. doi: 10.35541/cjd.20190757.
［23］	Zhu X, Zheng M, Song M,et al.Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque⁃type psoriasis: results from a phase 3 clinical trial （LOTUS）［J］.J Drugs Dermatol, 2013,12（2）:166⁃174. doi: 10.1111/j.1440⁃0960.2011.00770.x.
［24］	Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin⁃12/23 monoclonal antibody, in patients with psoriasis: 76⁃week results from a randomised, double⁃blind, placebo⁃controlled trial （PHOENIX 1）［J］. Lancet, 2008,371（9625）:1665⁃1674. doi: 10.1016/S0140⁃6736（08）60725⁃4.
［25］	Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin⁃12/23 monoclonal antibody, in patients with psoriasis: 52⁃week results from a randomised, double⁃blind, placebo⁃controlled trial （PHOENIX 2）［J］. Lancet, 2008,371（9625）:1675⁃1684. doi: 10.1016/S0140⁃6736（08）60726⁃6.
［26］	Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate⁃to⁃severe plaque psoriasis in paediatric patients （≥ 6 to < 12 years of age）: efficacy, safety, pharmacokinetic and biomarker results from the open⁃label CADMUS Jr study［J］. Br J Dermatol, 2020,183（4）:664⁃672. doi: 10.1111/bjd.19018.
［27］	Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate⁃to⁃severe psoriasis［J］. N Engl J Med, 2010,362（2）:118⁃128. doi: 10.1056/NEJMoa 0810652.
［28］	Cai L, Zhang JZ, Yao X, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis［J］. Chin Med J （Engl）, 2020,133（22）:2665⁃2673. doi: 10.1097/CM9.000000 0000001163.
［29］	Galluzzo M, D'Adamio S, Silvaggio D, et al. In which patients the best efficacy of secukinumab? Update of a real⁃life analysis after 136 weeks of treatment with secukinumab in moderate⁃to⁃severe plaque psoriasis［J］. Expert Opin Biol Ther, 2020,20（2）:173⁃182. doi: 10.1080/14712598.2020.1708897.
［30］	McInnes IB, Mease PJ, Kivitz AJ, et al. Long⁃term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5⁃year （end⁃of⁃study） results from the phase 3 FUTURE 2 study［J］. Lancet Rheumatol, 2020,2（4）:e227⁃e235. doi: 10.1016/S2665⁃9913（20）30036⁃9.
［31］	Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double⁃blind, randomised, phase 3 MAXIMISE trial［J］. Ann Rheum Dis, 2021,80（5）:582⁃590. doi: 10.1136/annrheumdis⁃2020⁃218808.
［32］	Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52⁃week results from a phase 3 double⁃blind randomized, controlled trial［J］. J Eur Acad Dermatol Venereol, 2021,35（4）:938⁃947. doi: 10.1111/jdv.17002.
［33］	Li X, Zheng J, Pan WL, et al. Efficacy and safety of ixekizumab in Chinese patients with moderate⁃to⁃severe plaque psoriasis: 60⁃week results from a phase 3 study［J］. Int J Dermatol Venereol, 2022,5（4）:181⁃190. doi: 10.1097/JD9.0000000000000244.
［34］	Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 Trials of ixekizumab in moderate⁃to⁃severe plaque psoriasis［J］. N Engl J Med, 2016,375（4）:345⁃356. doi: 10.1056/NEJMoa1512711.
［35］	Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24⁃week randomised, double⁃blind, placebo⁃controlled period of the SPIRIT⁃P2 phase 3 trial［J］. Lancet, 2017,389（10086）:2317⁃2327. doi: 10.1016/S0140⁃6736（17）31429⁃0.
［36］	Zhuang JY, Li JS, Zhong YQ, et al. Evaluation of short⁃term （16⁃week） effectiveness and safety of guselkumab in patients with psoriasis: a prospective real⁃life study on the Chinese population［J］. Dermatol Ther, 2021,34（5）:e15054. doi: 10.1111/dth. 15054.
［37］	Li Y, Lu JJ, Zhong XY, et al. Drug survival outcomes associated with the real⁃world use of ixekizumab, secukinumab, guselkumab, and adalimumab for the treatment of plaque psoriasis in china: a 52⁃week single⁃center retrospective study［J］. Clin Cosmet Investig Dermatol, 2022,15:2245⁃2252. doi: 10.2147/CCID.S387759.
［38］	Sofen H, Smith S, Matheson RT, et al. Guselkumab （an IL⁃23⁃specific mAb） demonstrates clinical and molecular response in patients with moderate⁃to⁃severe psoriasis［J］. J Allergy Clin Immunol, 2014,133（4）:1032⁃1040. doi: 10.1016/j.jaci.2014.01. 025.
［39］	Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase Ⅲ, double⁃blinded, placebo⁃ and active comparator⁃controlled VOYAGE 1 trial［J］. J Am Acad Dermatol, 2017,76（3）:405⁃417. doi: 10.1016/j.jaad.2016.11.041.
［40］	Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase Ⅲ, double⁃blind, placebo⁃ and active comparator⁃controlled VOYAGE 2 trial［J］. J Am Acad Dermatol, 2017,76（3）:418⁃431. doi: 10.1016/j.jaad.2016. 11.042.
［41］	Reich K, Griffiths C, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials［J］. J Am Acad Dermatol, 2020,82（4）:936⁃945. doi: 10.1016/j.jaad.2019.11.040.
［42］	Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic⁃naive or had previously received TNFα inhibitor treatment （DISCOVER⁃1）: a double⁃blind, randomised, placebo⁃controlled phase 3 trial［J］. Lancet, 2020,395（10230）:1115⁃1125. doi: 10.1016/S0140⁃6736（20）30265⁃8.
［43］	Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic⁃naive patients with active psoriatic arthritis （DISCOVER⁃2）: a double⁃blind, randomised, placebo⁃controlled phase 3 trial［J］. Lancet, 2020,395（10230）:1126⁃1136. doi: 10.1016/S0140⁃6736（20）30263⁃4.
［44］	Yu C, Geng S, Yang B, et al. Tildrakizumab for moderate⁃to⁃severe plaque psoriasis in Chinese patients: a 12⁃week randomized placebo⁃controlled phase Ⅲ trial with long⁃term extension［J］. Chin Med J （Engl）, 2024,137（10）:1190⁃1198. doi: 10.1097/CM9.0000000000002873.
［45］	Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis （reSURFACE 1 and reSURFACE 2）: results from two randomised controlled, phase 3 trials［J］. Lancet, 2017,390（10091）:276⁃288. doi: 10.1016/S0140⁃6736（17）31279⁃5.
［46］	Igarashi A, Nakagawa H, Morita A, et al. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: results from a 64⁃week phase 3 study （reSURFACE 1）［J］. J Dermatol, 2021,48（6）:853⁃863. doi: 10.1111/1346⁃8138.15789.
［47］	Reich K, Warren RB, Iversen L, et al. Long⁃term efficacy and safety of tildrakizumab for moderate⁃to⁃severe psoriasis: pooled analyses of two randomized phase Ⅲ clinical trials （reSURFACE 1 and reSURFACE 2） through 148 weeks［J］. Br J Dermatol, 2020,182（3）:605⁃617. doi: 10.1111/bjd.18232.
［48］	Thaçi D, Piaserico S, Gaarn Du Jardin K, et al. Long⁃term stability of PASI <3 response to tildrakizumab: pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials through 5 years［J］. J Eur Acad Dermatol Venereol, 2023,37（4）:e501⁃e504. doi: 10.1111/jdv.18783.
［49］	Thaci D, Piaserico S, Warren RB, et al. Five⁃year efficacy and safety of tildrakizumab in patients with moderate⁃to⁃severe psoriasis who respond at week 28: pooled analyses of two randomized phase Ⅲ clinical trials （reSURFACE 1 and reSURFACE 2）［J］. Br J Dermatol, 2021,185（2）:323⁃334. doi: 10.1111/bjd.19866.
［50］	Lebwohl MG, Leonardi CL, Mehta NN, et al. Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: long⁃term results from 2 phase 3 randomized controlled studies （reSURFACE 1 and reSURFACE 2）［J］. J Am Acad Dermatol, 2021,84（2）:398⁃407. doi: 10.1016/j.jaad.2020.09.047.
［51］	Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis［J］. N Engl J Med, 2021,385（26）:2431⁃2440. doi: 10.1056/NEJMoa2111563.
［52］	Morita A, Tsai TF, Yee E, et al. Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: results from the randomized, double⁃blind, placebo⁃controlled Effisayil™ 1 study［J］. J Dermatol, 2023,50（2）:183⁃194. doi: 10.1111/1346⁃8138.16609.
［53］	Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares （Effisayil 2）: an international, multicentre, randomised, placebo⁃controlled trial［J］. Lancet, 2023,402（10412）:1541⁃1551. doi: 10.1016/S0140⁃6736（23）01378⁃8.
［54］	Coates LC, Soriano ER, Corp N, et al. Group for research and assessment of psoriasis and psoriatic arthritis （GRAPPA）: updated treatment recommendations for psoriatic arthritis 2021［J］. Nat Rev Rheumatol, 2022,18（8）:465⁃479. doi: 10.1038/s41584⁃022⁃00798⁃0.
［55］	Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris ⁃ Part 2: specific clinical and comorbid situations［J］. J Eur Acad Dermatol Venereol, 2021,35（2）:281⁃317. doi: 10.1111/jdv.16926.
［56］	Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast monotherapy for long⁃term treatment of active psoriatic arthritis in DMARD⁃naïve patients［J］. Rheumatology （Oxford）, 2022,61（3）:1035⁃1043. doi: 10.1093/rheumatology/keab449.
［57］	Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate⁃to⁃severe plaque psoriasis over 52 weeks: a phase Ⅲ, randomized controlled trial （ESTEEM 2）［J］. Br J Dermatol, 2015,173（6）:1387⁃1399. doi: 10.1111/bjd.14164.
［58］	Stein Gold L, Papp K, Pariser D, et al. Efficacy and safety of apremilast in patients with mild⁃to⁃moderate plaque psoriasis: results of a phase 3, multicenter, randomized, double⁃blind, placebo⁃controlled trial［J］. J Am Acad Dermatol, 2022,86（1）:77⁃85. doi: 10.1016/j.jaad.2021.07.040.
［59］	Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 （PDE4） inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase Ⅲ, randomized, controlled trial （efficacy and safety trial evaluating the effects of apremilast in psoriasis ［ESTEEM］ 1）［J］. J Am Acad Dermatol, 2015,73（1）:37⁃49. doi: 10.1016/j.jaad.2015. 03.049.
［60］	McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis［J］. N Engl J Med, 2021,384（13）:1227⁃1239. doi: 10.1056/NEJMoa2022516.
［61］	McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non⁃biological therapy: 56⁃week data from the phase 3 SELECT⁃PsA 1 study［J］. RMD Open, 2021,7（3）:e001838. doi: 10.1136/rmdopen⁃2021⁃001838.
［62］	McInnes IB, Kato K, Magrey M, et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2⁃year results from the phase 3 SELECT⁃PsA 1 study［J］. Rheumatol Ther, 2023,10（1）:275⁃292. doi: 10.1007/s40744⁃022⁃00499⁃w.
［63］	Burmester GR, Cohen SB, Winthrop KL, et al. Safety profile of upadacitinib over 15 000 patient⁃years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis［J］. RMD Open, 2023,9（1）:e002735. doi: 10.1136/rmdopen⁃2022⁃002735.
［64］	Burmester GR, Winthrop K, Blanco R, et al. Safety profile of upadacitinib up to 3 years in psoriatic arthritis: an integrated analysis of two pivotal phase 3 trials［J］. Rheumatol Ther, 2022,9（2）:521⁃539. doi: 10.1007/s40744⁃021⁃00410⁃z.
［65］	Leng X, Lin W, Liu S, et al. Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double⁃blind, placebo⁃controlled study［J］. RMD Open, 2023,9（1）:e002559. doi: 10.1136/rmdopen⁃2022⁃002559.
［66］	Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis［J］. N Engl J Med, 2017,377（16）:1537⁃1550. doi: 10.1056/NEJMoa1615975.
［67］	Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52⁃week, randomized, double⁃blinded, placebo⁃controlled phase 3 POETYK PSO⁃1 trial［J］. J Am Acad Dermatol, 2023,88（1）:29⁃39. doi: 10.1016/j.jaad.2022.07.002.
［68］	Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52⁃week, randomized, double⁃blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial［J］. J Am Acad Dermatol, 2023,88（1）:40⁃51. doi: 10.1016/j.jaad.2022.08.061.
［69］	Imafuku S, Tada Y, Hippeli L, et al. Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: subgroup analysis of a randomized, double⁃blind, placebo⁃controlled, global phase 3 trial［J］. J Dermatol, 2023,50（5）:588⁃595. doi: 10.1111/1346⁃8138.16740.
［70］	Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris ⁃ part 1: treatment and monitoring recommendations［J］. J Eur Acad Dermatol Venereol, 2020,34（11）:2461⁃2498. doi: 10.1111/jdv.16915.
［71］	Nast A, Altenburg A, Augustin M, et al. German S3⁃Guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm ⁃ Part 1: treatment goals and treatment recommendations［J］. J Dtsch Dermatol Ges, 2021,19（6）:934⁃150. doi: 10.1111/ddg.14508.
［72］	Mease PJ, Hatemi G, Paris M, et al. Apremilast long⁃term safety up to 5 years from 15 pooled randomized, placebo⁃controlled studies of psoriasis, psoriatic arthritis, and Behçet's syndrome［J］. Am J Clin Dermatol, 2023,24（5）:809⁃820. doi: 10.1007/s40257⁃023⁃00783⁃7.
［73］	Lambert J, Segaert S, Ghislain PD, et al. Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history （BETA⁃PSO: Belgian evidence⁃based treatment advice in psoriasis; part 1）［J］. J Eur Acad Dermatol Venereol, 2020,34（8）:1654⁃1665. doi: 10.1111/jdv.16684.
［74］	Lambert J, Segaert S, Ghislain PD, et al. Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders （BETA⁃PSO: Belgian evidence⁃based treatment advice in psoriasis; part 2）［J］. J Eur Acad Dermatol Venereol, 2020,34（9）:1914⁃1923. doi: 10.1111/jdv.16683.
［75］	de la Cueva Dobao P, Notario J, Ferrándiz C, et al. Expert consensus on the persistence of biological treatments in moderate⁃to⁃severe psoriasis［J］. J Eur Acad Dermatol Venereol, 2019,33（7）:1214⁃1223. doi: 10.1111/jdv.15600.
［76］	Saeki H, Mabuchi T, Asahina A, et al. English version of Japanese guidance for the use of oral Janus kinase inhibitors （JAK1 and TYK2 inhibitors） in the treatments of psoriasis［J］. J Dermatol, 2023,50（5）:e138⁃e150. doi: 10.1111/1346⁃8138. 16797.
［77］	Lebwohl MG, Kircik L, Callis Duffin K, et al. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis［J］. J Am Acad Dermatol, 2013,69（3）:385⁃392. doi: 10.1016/j.jaad.2013.03.031.
［78］	Okubo Y, Takahashi H, Hino R, et al. Efficacy and safety of apremilast in the treatment of patients with mild⁃to⁃moderate psoriasis in Japan: results from PROMINENT, a phase 3b, open⁃label, single⁃arm study［J］. Dermatol Ther （Heidelb）, 2022,12（6）:1469⁃1480. doi: 10.1007/s13555⁃022⁃00747⁃5.
［79］	Armstrong AW, Bagel J, Van Voorhees AS, et al. Combining biologic therapies with other systemic treatments in psoriasis: evidence⁃based, best⁃practice recommendations from the medical board of the national psoriasis foundation［J］. JAMA Dermatol, 2015,151（4）:432⁃438. doi: 10.1001/jamadermatol. 2014.3456.
［80］	Di Lernia V, Albertini G. Is antitumour necrosis factor therapy combined with ultraviolet B phototherapy safe?［J］. Br J Dermatol, 2010,162（5）:1147⁃1148. doi: 10.1111/j.1365⁃2133. 2010.09663.x.
［81］	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物治疗专家共识（2019）［J］. 中华皮肤科杂志, 2019,52（12）:863⁃871. doi: 10.35541/cjd.20190892
［82］	van der Kraaij G, Busard C, van den Reek J, et al. Adalimumab with methotrexate vs. adalimumab monotherapy in psoriasis: first⁃year results of a single⁃blind randomized controlled trial［J］. J Invest Dermatol, 2022,142（9）:2375⁃2383.e6. doi: 10.1016/j.jid.2022.01.033.
［83］	Benzaquen M, Munshi M, Bossart S, et al. Long⁃term dose optimization of adalimumab via dose spacing in patients with psoriasis［J］. Bioengineering （Basel）, 2022,9（8）:387. doi: 10. 3390/bioengineering9080387.
［84］	García⁃Beloso N, Altabás⁃González I, Samartín⁃Ucha M, et al. Switching between reference adalimumab and biosimilars in chronic immune⁃mediated inflammatory diseases: a systematic literature review［J］. Br J Clin Pharmacol, 2022,88（4）:1529⁃1550. doi: 10.1111/bcp.15101.
［85］	Pina Vegas L, Le Corvoisier P, Penso L, et al. Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study［J］. Rheumatology （Oxford）, 2022,61（4）:1589⁃1599. doi: 10.1093/rheumatology/keab522.
［86］	杨琦, 郑捷. 生物制剂治疗对银屑病相关心血管疾病的影响［J］. 中华皮肤科杂志, 2023,56（2）:165⁃169. doi: 10.35541/cjd.20200649.
［87］	Gkalpakiotis S, Arenbergerova M, Gkalpakioti P, et al. Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: results of a pilot study［J］. J Dermatol, 2017,44（4）:363⁃369. doi: 10.1111/1346⁃8138.13661.
［88］	AbuHilal M, Walsh S, Shear N. Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a retrospective study［J］. J Cutan Med Surg, 2016,20（4）:313⁃316. doi: 10.1177/1203475416631328.
［89］	Diotallevi F, Paolinelli M, Radi G, et al. Latest combination therapies in psoriasis: narrative review of the literature［J］. Dermatol Ther, 2022,35（10）:e15759. doi: 10.1111/dth.15759.
［90］	Hanna S, Youssef P, Lowe P. Novel combination biologic therapy for recalcitrant psoriasis and psoriatic arthritis in a medically complex patient［J］. Australas J Dermatol, 2022,63（1）:e63⁃e66. doi: 10.1111/ajd.13752.
［91］	Torres T, Tavares Bello R, Paiva Lopes MJ, et al. Portuguese recommendations for the treatment of psoriasis with biologic therapy［J］. Eur J Dermatol, 2020,30（6）:645⁃654. doi: 10.1684/ejd.2020.3945.
［92］	Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis （the 2019 version）［J］. J Dermatol, 2020,47（3）:201⁃222. doi: 10.1111/1346⁃8138.15196.
［93］	Amatore F, Villani AP, Tauber M, et al. French guidelines on the use of systemic treatments for moderate⁃to⁃severe psoriasis in adults［J］. J Eur Acad Dermatol Venereol, 2019,33（3）:464⁃483. doi: 10.1111/jdv.15340.
［94］	Smith CH, Yiu Z, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update［J］. Br J Dermatol, 2020,183（4）:628⁃637. doi: 10.1111/bjd.19039.
［95］	Kleinrensink NJ, Perton FT, Pouw JN, et al. TOFA⁃PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug⁃free remission in psoriatic arthritis （PsA）［J］. BMJ Open, 2022,12（10）:e064338. doi: 10.1136/bmjopen⁃2022⁃064338.
［96］	Phatak S, Khenat A, Malandkar M, et al. Effectiveness and safety of generic tofacitinib in spondyloarthritis: a real⁃world retrospective analysis from India［J］. Int J Rheum Dis, 2023,26（3）:487⁃492. doi: 10.1111/1756⁃185X.14570.
［97］	Balakirski G, Gerdes S, Beissert S, et al. Therapy of psoriasis during pregnancy and breast⁃feeding［J］. J Dtsch Dermatol Ges, 2022,20（5）:653⁃683. doi: 10.1111/ddg.14789.
［98］	Bronckers IM, Paller AS, van Geel MJ, et al. Psoriasis in children and adolescents: diagnosis, management and comorbidities［J］. Paediatr Drugs, 2015,17（5）:373⁃384. doi: 10.1007/s40272⁃015⁃0137⁃1.
［99］	Fabrizi G, Guerriero C, Pagliarello C. Etanercept in infants: suberythrodermic, recalcitrant psoriasis in a 22 month⁃old child successfully treated with etanercept［J］. Eur J Dermatol, 2007,17（3）:245. doi: 10.1684/ejd.2007.0159.
［100］	AlMutairi N, Nour T. Tofacitinib in pediatric psoriasis: an open⁃label trial to study its safety and efficacy in children［J］. Dermatology, 2020,236（3）:191⁃198. doi: 10.1159/000503062.
［101］	Gargiulo L, Ibba L, Pavia G, et al. Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series［J］. J Dermatolog Treat, 2023,34（1）:2183729. doi: 10.1080/09546634.2023.2183729.
［102］	Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF⁃α antagonists: a systematic review and meta⁃analysis of randomised controlled trials［J］. BMJ Open, 2017,7（3）:e012567. doi: 10.1136/bmjopen⁃2016⁃012567.
［103］	国家卫生健康委员会办公厅. 国家卫生健康委办公厅关于印发中国结核病预防控制工作技术规范（2020年版）的通知［EB/OL］. （2020⁃04⁃14）. https://www.sohu.com/a/387919909_771405.
［104］	Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin （IL）⁃17 and IL⁃23 inhibitors in psoriasis ⁃ time for a paradigm change［J］. J Eur Acad Dermatol Venereol, 2021,35（4）:824⁃834. doi: 10.1111/jdv.16866.
［105］	Elewski BE, Baddley JW, Deodhar AA, et al. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis［J］. JAMA Dermatol, 2021,157（1）:43⁃51. doi: 10. 1001/jamadermatol.2020.3257.
［106］	Shu D, Zhang Z, Zhou EY, et al. Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving IL⁃17 inhibitors? A cohort study［J］. Dermatol Ther, 2020,33（6）:e14512. doi: 10.1111/dth.14512.
［107］	肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识［J］. 中华风湿病学杂志, 2013,17（8）:508⁃512. doi: 10.3760/cma.j.issn.1007⁃7480.2013.08.002.
［108］	Abignano G, Fadl N, Merashli M, et al. Apremilast for the treatment of active psoriatic arthritis: a single⁃centre real⁃life experience［J］. Rheumatology （Oxford）, 2018,57（3）:578⁃580. doi: 10.1093/rheumatology/kex454.
［109］	Crowley J, Thaçi D, Joly P, et al. Long⁃term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials （ESTEEM 1 and 2）［J］. J Am Acad Dermatol, 2017,77（2）:310⁃317.e1. doi: 10.1016/j.jaad.2017.01.052.
［110］	Favalli EG, Conti F, Selmi C, et al. Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients［J］. Clin Exp Rheumatol, 2020,38（1）:19⁃26.
［111］	Adam DN, Gooderham MJ, Beecker JR, et al. Expert consensus on the systemic treatment of atopic dermatitis in special populations［J］. J Eur Acad Dermatol Venereol, 2023,37（6）:1135⁃1148. doi: 10.1111/jdv.18922.
［112］	Ogawa E, Wei MT, Nguyen MH. Hepatitis B virus reactivation potentiated by biologics［J］. Infect Dis Clin North Am, 2020,34（2）:341⁃358. doi: 10.1016/j.idc.2020.02.009.
［113］	Papatheodoridis GV, Lekakis V, Voulgaris T, et al. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta⁃analysis, and expert opinion［J］. J Hepatol, 2022,77（6）:1670⁃1689. doi: 10.1016/j.jhep.2022.07.003.
［114］	Lee MP, Wu KK, Lee EB, et al. Risk for deep fungal infections during IL⁃17 and IL⁃23 inhibitor therapy for psoriasis［J］. Cutis, 2020,106（4）:199⁃205. doi: 10.12788/cutis.0088.
［115］	Tragiannidis A, Kyriakidis I, Zündorf I, et al. Invasive fungal infections in pediatric patients treated with tumor necrosis alpha （TNF⁃α） inhibitors［J］. Mycoses, 2017,60（4）:222⁃229. doi: 10.1111/myc.12576.
［116］	El Hayderi L, Colson F, Dezfoulian B, et al. Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges［J］. Psoriasis （Auckl）, 2016,6:145⁃151. doi: 10.2147/PTT.S102202.
［117］	Shalom G, Naldi L, Lebwohl M, et al. Biological treatment for psoriasis and the risk of herpes zoster: results from the psoriasis longitudinal assessment and registry （PSOLAR）［J］. J Dermatolog Treat, 2019,30（6）:534⁃539. doi: 10.1080/095466 34.2018.1445193.
［118］	Baumrin E, Van Voorhees A, Garg A, et al. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: from the medical board of the national psoriasis foundation［J］. J Am Acad Dermatol, 2019,81（1）:102⁃110. doi: 10.1016/j.jaad.2019.03.017.
［119］	Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis［J］. JAMA, 2006,296（14）:1735⁃1741. doi: 10.1001/jama.296.14.1735.
［120］	Wang X, Kaiser H, Kvist⁃Hansen A, et al. IL⁃17 pathway members as potential biomarkers of effective systemic treatment and cardiovascular disease in patients with moderate⁃to⁃severe psoriasis［J］. Int J Mol Sci, 2022,23（1）:555. doi: 10.3390/ijms 23010555.
［121］	Wu JJ, Poon KY, Channual JC, et al. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis［J］. Arch Dermatol, 2012,148（11）:1244⁃1250. doi: 10.1001/archdermatol.2012.2502.
［122］	Gelfand JM, Shin DB, Armstrong AW, et al. Association of apremilast with vascular inflammation and cardiometabolic function in patients with psoriasis: the VIP⁃A phase 4, open⁃label, nonrandomized clinical trial［J］. JAMA Dermatol, 2022,158（12）:1394⁃1403. doi: 10.1001/jamadermatol.2022.3862.
［123］	Otto M, Dorn B, Grasmik T, et al. Apremilast effectively inhibits TNFα⁃induced vascular inflammation in human endothelial cells［J］. J Eur Acad Dermatol Venereol, 2022,36（2）:237⁃246. doi: 10.1111/jdv.17769.
［124］	Kume K, Amano K, Yamada S, et al. Tofacitinib improves atherosclerosis despite up⁃regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study［J］. Rheumatol Int, 2017,37（12）:2079⁃2085. doi: 10.1007/s00296⁃017⁃3844⁃9.
［125］	Charles⁃Schoeman C, DeMasi R, Valdez H, et al. Risk factors for major adverse cardiovascular events in phase Ⅲ and long⁃term extension studies of tofacitinib in patients with rheumatoid arthritis［J］. Arthritis Rheumatol, 2019,71（9）:1450⁃1459. doi: 10.1002/art.40911.
［126］	Gladman DD, Charles⁃Schoeman C, McInnes IB, et al. Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis across phase Ⅲ and long⁃term extension studies［J］. Arthritis Care Res （Hoboken）, 2019,71（10）:1387⁃1395. doi: 10.1002/acr.23930.
［127］	Khosrow⁃Khavar F, Desai RJ, Lee H, et al. Tofacitinib and risk of malignancy: results from the safety of tofacitinib in routine care patients with rheumatoid arthritis （STAR⁃RA） study［J］. Arthritis Rheumatol, 2022,74（10）:1648⁃1659. doi: 10.1002/art.42250.
［128］	Hoisnard L, Pina Vegas L, Dray⁃Spira R, et al. Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study［J］. Ann Rheum Dis, 2023,82（2）:182⁃188. doi: 10.1136/ard⁃2022⁃222824.
［129］	Bhatia N, Heim J, Schenkel B, et al. Quality of life and patient⁃reported symptoms in a phase 4, real⁃world study of tildrakizumab in patients with moderate⁃to⁃severe psoriasis: week 28 interim analysis［J］. J Dermatolog Treat, 2023,34（1）:2200872. doi: 10.1080/09546634.2023.2200872.
［130］	Mease PJ, Chohan S, Fructuoso F, et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double⁃blind, placebo⁃controlled, multiple⁃dose, 52⁃week phase Ⅱb study［J］. Ann Rheum Dis, 2021,80（9）:1147⁃1157. doi: 10.1136/annrheumdis⁃2020⁃219014.
［131］	Plachouri KM, Georgiou S. Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus （HIV） infection, and pediatric psoriasis［J］. Int J Dermatol, 2019,58（9）:1008⁃1013. doi: 10.1111/ijd.14436.
［132］	Stephan B, Tittelbach J, Bühler S. Considerations for patients with psoriasis travelling under immunosuppression［J］. J Dtsch Dermatol Ges, 2021,19（2）:197⁃207. doi: 10.1111/ddg.14377.
［133］	Poelman SM, Keeling CP, Metelitsa AI. Practical guidelines for managing patients with psoriasis on biologics: an update［J］. J Cutan Med Surg, 2019,23（1_suppl）:3S⁃12S. doi: 10.1177/1203475418811347.
［134］	Smith CH, Jabbar⁃Lopez ZK, Yiu ZZ, et al. British association of dermatologists guidelines for biologic therapy for psoriasis 2017［J］. Br J Dermatol, 2017,177（3）:628⁃636. doi: 10.1111/bjd.15665.
［135］	Curtis JR, Johnson SR, Anthony DD, et al. American college of rheumatology guidance for COVID⁃19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3［J］. Arthritis Rheumatol, 2021,73（10）:e60⁃e75. doi: 10.1002/art. 41928.
［136］	Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases［J］. Ann Rheum Dis, 2020,79（1）:39⁃52. doi: 10.1136/annrheumdis⁃2019⁃215882.
［137］	Sacchelli L, Magnano M, Loi C, et al. The unforeseen during biotechnological therapy for moderate⁃to⁃severe psoriasis: how to manage pregnancy and breastfeeding, infections from mycobacterium tuberculosis, hepatitis B virus, hepatitis C virus, and HIV, surgery, vaccinations, diagnosis of malignancy, and dose tapering［J］. Dermatol Ther, 2020,33（3）:e13411. doi: 10.1111/dth.13411.
［138］	Körber A, Augustin M, Behrens F, et al. Treatment of psoriasis with secukinumab: practical guidance［J］. Hautarzt, 2021,72（11）:984⁃991. doi: 10.1007/s00105⁃021⁃04871⁃9.
［139］	Albrecht K, Leipe J. Continue or interrupt? Antirheumatic treatment in elective surgery［J］. Z Rheumatol, 2022,81（6）:492⁃500. doi: 10.1007/s00393⁃022⁃01236⁃y.

[1]	Qiao Jiaxi, Xia Ping, Chen Liuqing. Analysis of dermoscopic and reflectance confocal microscopic features of psoriatic lesions before and after treatment with secukinumab [J]. Chinese Journal of Dermatology, 2024, 57(9): 825-829.
[2]	Lin Ziyuan, Pang Tianyi, Wu Jingwen, Jin Hui, . Role of polycyclic aromatic hydrocarbons in the occurrence and development of inflammatory skin diseases [J]. Chinese Journal of Dermatology, 2024, 57(8): 765-769.
[3]	Dou Jinfa, Wang Jianbo, Zhang Shuai, Li Jianguo, Liu Hongwei, Zhang Shoumin. Analysis of changes in disease status and their influencing factors in patients with moderate to severe plaque psoriasis receiving biologic therapy during the coronavirus disease 2019 pandemic: a single-center cross-sectional study [J]. Chinese Journal of Dermatology, 2024, 57(8): 739-742.
[4]	Sui Changlin, Chang Xiao, Zhao Qi, Zhu Wei. Psoriasis induced by anti-tumor targeted therapy and immunotherapy [J]. Chinese Journal of Dermatology, 2024, 57(6): 570-574.
[5]	aser Cosmetology Group, Medical Aesthetics and Cosmetology Branch of Chinese Medical Association, Skin Care Product and Material Group, Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment, Laser Group, Cosmetic and Plastic Surgeon Branch of Chinese Medical Doctor Association, Cosmetic Laser Group, Chinese Society of Dermatology. Guidelines for the diagnosis and treatment of adverse skin reactions to cosmetics （2024 edition） [J]. Chinese Journal of Dermatology, 2024, 57(6): 485-492.
[6]	Working Group on “Expert consensus on clinical use of secukinumab in the treatment of psoriasis”. Expert consensus on clinical use of secukinumab in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(5): 20240226-e20240226.
[7]	Hu Mengyao, Li Min, Chen Sihan, Wei Xuecui, Chen Yujie, Xu Song, Chen Xu, . Different regulatory effects of S100A8/A9 expressed by keratinocytes in three common inflammatory skin injury modes [J]. Chinese Journal of Dermatology, 2024, 57(5): 435-444.
[8]	China Dermatologist Association. Guidelines for the management of chronic pruritus （2024） [J]. Chinese Journal of Dermatology, 2024, 57(5): 387-399.
[9]	China Dermatologist Association, Combination of Traditional and Western Medicine Dermatology. Diagnosis and treatment of erythrodermic psoriasis: a Chinese expert consensus statement （2024） [J]. Chinese Journal of Dermatology, 2024, 57(5): 409-417.
[10]	Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2024, 57(5): 479-482.
[11]	Zhang Yuanwen, Sun Congqian, Pan Wendong. Off-label clinical application of botulinum toxin in dermatology [J]. Chinese Journal of Dermatology, 2024, 57(5): 471-475.
[12]	Ye Hui, Xue Rujun, Zhang Xibao. Application of biological therapies and mechanisms of immunophenotypic switching in psoriasis and atopic dermatitis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220795-e20220795.
[13]	Yuan Liyan, Yu Xiaoling, Wang Xiaohua, Yang Bin. TYK2 inhibitors for plaque psoriasis: mechanism of action and advances in clinical research [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220740-e0220740.
[14]	Wei Lu, Wang Chang, Zhang Buxin, Xu Juntao, Wang Li, Wang Qingxing, Lu Lingling, Liu Aimin. Gender differences in psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230200-e20230200.
[15]	Zhu Tingting, Zhang Xuejun. Apremilast in the treatment of plaque psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230448-e20230448.

Guidelines for the treatment of psoriasis with biologics and small-molecule drugs in China （2024）

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［139］

Related Articles 15

Metrics

Comments

Recommended 10